Immunic Reports Phase 2 CALLIPER Trial Results for Vidofludimus Calcium

Immunic AG has announced significant outcomes from its Phase 2 CALLIPER trial concerning its drug vidofludimus calcium (IMU-838) in progressive multiple sclerosis (PMS) patients. The trial revealed a 30% reduction in the risk of disability worsening for patients with primary progressive multiple sclerosis (PPMS) compared to placebo.

In total, the drug reduced disability progression risk by 20% across the broader study population. This benefit was especially pronounced in patients lacking inflammatory lesions at baseline, with a 29% risk reduction. The annualized rate of thalamic brain volume loss also saw a 20% reduction compared to placebo, highlighting potential neuroprotective effects previously observed with the drug.

Favorable safety and tolerability profiles were confirmed, aligning with previous trials. No new safety signals emerged, suggesting a positive outlook for future phases. Immunic plans to continue its efforts into Phase 3 to further assess the drug's potential in treating progressive forms of multiple sclerosis.